PCA3 and prostate carcinoma: Overall,our proof-of-concept Tb-to-QD TR-FRET assay demonstrated the potentialfor rapid and simple PCA3 quantification at low nanomolar concentrationsusing two commercially available plate reader systems, suggestingits value as a tool for prostate cancer analysis in both researchand clinical laboratories.